Mitochondrial GSH replenishment as a potential therapeutic approach for Niemann Pick type C disease
Niemann Pick type C (NPC) disease is a progressive lysosomal storage disorder caused by mutations in genes encoding NPC1/NPC2 proteins, characterized by neurological defects, hepatosplenomegaly and premature death. While the primary biochemical feature of NPC disease is the intracellular accumulatio...
| Main Authors: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2017-04-01
|
| Series: | Redox Biology |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2213231716302567 |
| _version_ | 1811327783292370944 |
|---|---|
| author | Sandra Torres Nuria Matías Anna Baulies Susana Nuñez Cristina Alarcon-Vila Laura Martinez Natalia Nuño Anna Fernandez Joan Caballeria Thierry Levade Alba Gonzalez-Franquesa Pablo Garcia-Rovés Elisa Balboa Silvana Zanlungo Gemma Fabrías Josefina Casas Carlos Enrich Carmen Garcia-Ruiz José C. Fernández-Checa |
| author_facet | Sandra Torres Nuria Matías Anna Baulies Susana Nuñez Cristina Alarcon-Vila Laura Martinez Natalia Nuño Anna Fernandez Joan Caballeria Thierry Levade Alba Gonzalez-Franquesa Pablo Garcia-Rovés Elisa Balboa Silvana Zanlungo Gemma Fabrías Josefina Casas Carlos Enrich Carmen Garcia-Ruiz José C. Fernández-Checa |
| author_sort | Sandra Torres |
| collection | DOAJ |
| description | Niemann Pick type C (NPC) disease is a progressive lysosomal storage disorder caused by mutations in genes encoding NPC1/NPC2 proteins, characterized by neurological defects, hepatosplenomegaly and premature death. While the primary biochemical feature of NPC disease is the intracellular accumulation of cholesterol and gangliosides, predominantly in endolysosomes, mitochondrial cholesterol accumulation has also been reported. As accumulation of cholesterol in mitochondria is known to impair the transport of GSH into mitochondria, resulting in mitochondrial GSH (mGSH) depletion, we investigated the impact of mGSH recovery in NPC disease. We show that GSH ethyl ester (GSH-EE), but not N-acetylcysteine (NAC), restored the mGSH pool in liver and brain of Npc1-/- mice and in fibroblasts from NPC patients, while both GSH-EE and NAC increased total GSH levels. GSH-EE but not NAC increased the median survival and maximal life span of Npc1-/- mice. Moreover, intraperitoneal therapy with GSH-EE protected against oxidative stress and oxidant-induced cell death, restored calbindin levels in cerebellar Purkinje cells and reversed locomotor impairment in Npc1-/- mice. High-resolution respirometry analyses revealed that GSH-EE improved oxidative phosphorylation, coupled respiration and maximal electron transfer in cerebellum of Npc1-/- mice. Lipidomic analyses showed that GSH-EE treatment had not effect in the profile of most sphingolipids in liver and brain, except for some particular species in brain of Npc1-/- mice. These findings indicate that the specific replenishment of mGSH may be a potential promising therapy for NPC disease, worth exploring alone or in combination with other options. Keywords: Ceramide, Sphingolipids, Mitochondrial GSH, Cerebellum, Hepatosplenomegaly, Lysosomal disorders |
| first_indexed | 2024-04-13T15:14:11Z |
| format | Article |
| id | doaj.art-2f56652c5022467eb14c86c368ed286a |
| institution | Directory Open Access Journal |
| issn | 2213-2317 |
| language | English |
| last_indexed | 2024-04-13T15:14:11Z |
| publishDate | 2017-04-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Redox Biology |
| spelling | doaj.art-2f56652c5022467eb14c86c368ed286a2022-12-22T02:41:54ZengElsevierRedox Biology2213-23172017-04-01116072Mitochondrial GSH replenishment as a potential therapeutic approach for Niemann Pick type C diseaseSandra Torres0Nuria Matías1Anna Baulies2Susana Nuñez3Cristina Alarcon-Vila4Laura Martinez5Natalia Nuño6Anna Fernandez7Joan Caballeria8Thierry Levade9Alba Gonzalez-Franquesa10Pablo Garcia-Rovés11Elisa Balboa12Silvana Zanlungo13Gemma Fabrías14Josefina Casas15Carlos Enrich16Carmen Garcia-Ruiz17José C. Fernández-Checa18Cell Death and Proliferation, Institute of Biomedical Research of Barcelona (IIBB), CSIC, Barcelona, Spain; Liver Unit, Hospital Clinic I Provincial de Barcelona, IDIBAPS and CIBERehd, Barcelona, SpainCell Death and Proliferation, Institute of Biomedical Research of Barcelona (IIBB), CSIC, Barcelona, Spain; Liver Unit, Hospital Clinic I Provincial de Barcelona, IDIBAPS and CIBERehd, Barcelona, SpainCell Death and Proliferation, Institute of Biomedical Research of Barcelona (IIBB), CSIC, Barcelona, Spain; Liver Unit, Hospital Clinic I Provincial de Barcelona, IDIBAPS and CIBERehd, Barcelona, SpainCell Death and Proliferation, Institute of Biomedical Research of Barcelona (IIBB), CSIC, Barcelona, Spain; Liver Unit, Hospital Clinic I Provincial de Barcelona, IDIBAPS and CIBERehd, Barcelona, SpainCell Death and Proliferation, Institute of Biomedical Research of Barcelona (IIBB), CSIC, Barcelona, Spain; Liver Unit, Hospital Clinic I Provincial de Barcelona, IDIBAPS and CIBERehd, Barcelona, SpainCell Death and Proliferation, Institute of Biomedical Research of Barcelona (IIBB), CSIC, Barcelona, Spain; Liver Unit, Hospital Clinic I Provincial de Barcelona, IDIBAPS and CIBERehd, Barcelona, SpainCell Death and Proliferation, Institute of Biomedical Research of Barcelona (IIBB), CSIC, Barcelona, Spain; Liver Unit, Hospital Clinic I Provincial de Barcelona, IDIBAPS and CIBERehd, Barcelona, SpainCell Death and Proliferation, Institute of Biomedical Research of Barcelona (IIBB), CSIC, Barcelona, Spain; Liver Unit, Hospital Clinic I Provincial de Barcelona, IDIBAPS and CIBERehd, Barcelona, SpainLiver Unit, Hospital Clinic I Provincial de Barcelona, IDIBAPS and CIBERehd, Barcelona, SpainInstitut National de la Santé et de la Recherche Médicale (INSERM) UMR1037, Centre de Recherches en Cancerologie de Toulouse, Toulouse, FranceDiabetes and Obesity Research Laboratory, Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS) and Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders (CIBERDEM), Barcelona, SpainDiabetes and Obesity Research Laboratory, Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS) and Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders (CIBERDEM), Barcelona, SpainDepartamento de Gastroenterología, Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, ChileDepartamento de Gastroenterología, Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, ChileResearch Unit on BioActive Molecules (RUBAM), Departament de Química Orgànica Biològica, Institut d’Investigacions Químiques i Ambientals de Barcelona, Consejo Superior de Investigaciones Científicas (CSIC), Barcelona, SpainResearch Unit on BioActive Molecules (RUBAM), Departament de Química Orgànica Biològica, Institut d’Investigacions Químiques i Ambientals de Barcelona, Consejo Superior de Investigaciones Científicas (CSIC), Barcelona, SpainCentre de Recerca Biomèdica CELLEX, Institut d′Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Spain; Departament de Biologia Cel·lular, Immunologia i Neurociències, Facultat de Medicina, Universitat de Barcelona, 08036 Barcelona, SpainCell Death and Proliferation, Institute of Biomedical Research of Barcelona (IIBB), CSIC, Barcelona, Spain; Liver Unit, Hospital Clinic I Provincial de Barcelona, IDIBAPS and CIBERehd, Barcelona, Spain; Research Center for ALPD, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States; Corresponding authors at: Cell Death and Proliferation, Institute of Biomedical Research of Barcelona (IIBB), CSIC, Barcelona, SpainCell Death and Proliferation, Institute of Biomedical Research of Barcelona (IIBB), CSIC, Barcelona, Spain; Liver Unit, Hospital Clinic I Provincial de Barcelona, IDIBAPS and CIBERehd, Barcelona, Spain; Research Center for ALPD, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States; Corresponding authors at: Cell Death and Proliferation, Institute of Biomedical Research of Barcelona (IIBB), CSIC, Barcelona, SpainNiemann Pick type C (NPC) disease is a progressive lysosomal storage disorder caused by mutations in genes encoding NPC1/NPC2 proteins, characterized by neurological defects, hepatosplenomegaly and premature death. While the primary biochemical feature of NPC disease is the intracellular accumulation of cholesterol and gangliosides, predominantly in endolysosomes, mitochondrial cholesterol accumulation has also been reported. As accumulation of cholesterol in mitochondria is known to impair the transport of GSH into mitochondria, resulting in mitochondrial GSH (mGSH) depletion, we investigated the impact of mGSH recovery in NPC disease. We show that GSH ethyl ester (GSH-EE), but not N-acetylcysteine (NAC), restored the mGSH pool in liver and brain of Npc1-/- mice and in fibroblasts from NPC patients, while both GSH-EE and NAC increased total GSH levels. GSH-EE but not NAC increased the median survival and maximal life span of Npc1-/- mice. Moreover, intraperitoneal therapy with GSH-EE protected against oxidative stress and oxidant-induced cell death, restored calbindin levels in cerebellar Purkinje cells and reversed locomotor impairment in Npc1-/- mice. High-resolution respirometry analyses revealed that GSH-EE improved oxidative phosphorylation, coupled respiration and maximal electron transfer in cerebellum of Npc1-/- mice. Lipidomic analyses showed that GSH-EE treatment had not effect in the profile of most sphingolipids in liver and brain, except for some particular species in brain of Npc1-/- mice. These findings indicate that the specific replenishment of mGSH may be a potential promising therapy for NPC disease, worth exploring alone or in combination with other options. Keywords: Ceramide, Sphingolipids, Mitochondrial GSH, Cerebellum, Hepatosplenomegaly, Lysosomal disordershttp://www.sciencedirect.com/science/article/pii/S2213231716302567 |
| spellingShingle | Sandra Torres Nuria Matías Anna Baulies Susana Nuñez Cristina Alarcon-Vila Laura Martinez Natalia Nuño Anna Fernandez Joan Caballeria Thierry Levade Alba Gonzalez-Franquesa Pablo Garcia-Rovés Elisa Balboa Silvana Zanlungo Gemma Fabrías Josefina Casas Carlos Enrich Carmen Garcia-Ruiz José C. Fernández-Checa Mitochondrial GSH replenishment as a potential therapeutic approach for Niemann Pick type C disease Redox Biology |
| title | Mitochondrial GSH replenishment as a potential therapeutic approach for Niemann Pick type C disease |
| title_full | Mitochondrial GSH replenishment as a potential therapeutic approach for Niemann Pick type C disease |
| title_fullStr | Mitochondrial GSH replenishment as a potential therapeutic approach for Niemann Pick type C disease |
| title_full_unstemmed | Mitochondrial GSH replenishment as a potential therapeutic approach for Niemann Pick type C disease |
| title_short | Mitochondrial GSH replenishment as a potential therapeutic approach for Niemann Pick type C disease |
| title_sort | mitochondrial gsh replenishment as a potential therapeutic approach for niemann pick type c disease |
| url | http://www.sciencedirect.com/science/article/pii/S2213231716302567 |
| work_keys_str_mv | AT sandratorres mitochondrialgshreplenishmentasapotentialtherapeuticapproachforniemannpicktypecdisease AT nuriamatias mitochondrialgshreplenishmentasapotentialtherapeuticapproachforniemannpicktypecdisease AT annabaulies mitochondrialgshreplenishmentasapotentialtherapeuticapproachforniemannpicktypecdisease AT susananunez mitochondrialgshreplenishmentasapotentialtherapeuticapproachforniemannpicktypecdisease AT cristinaalarconvila mitochondrialgshreplenishmentasapotentialtherapeuticapproachforniemannpicktypecdisease AT lauramartinez mitochondrialgshreplenishmentasapotentialtherapeuticapproachforniemannpicktypecdisease AT natalianuno mitochondrialgshreplenishmentasapotentialtherapeuticapproachforniemannpicktypecdisease AT annafernandez mitochondrialgshreplenishmentasapotentialtherapeuticapproachforniemannpicktypecdisease AT joancaballeria mitochondrialgshreplenishmentasapotentialtherapeuticapproachforniemannpicktypecdisease AT thierrylevade mitochondrialgshreplenishmentasapotentialtherapeuticapproachforniemannpicktypecdisease AT albagonzalezfranquesa mitochondrialgshreplenishmentasapotentialtherapeuticapproachforniemannpicktypecdisease AT pablogarciaroves mitochondrialgshreplenishmentasapotentialtherapeuticapproachforniemannpicktypecdisease AT elisabalboa mitochondrialgshreplenishmentasapotentialtherapeuticapproachforniemannpicktypecdisease AT silvanazanlungo mitochondrialgshreplenishmentasapotentialtherapeuticapproachforniemannpicktypecdisease AT gemmafabrias mitochondrialgshreplenishmentasapotentialtherapeuticapproachforniemannpicktypecdisease AT josefinacasas mitochondrialgshreplenishmentasapotentialtherapeuticapproachforniemannpicktypecdisease AT carlosenrich mitochondrialgshreplenishmentasapotentialtherapeuticapproachforniemannpicktypecdisease AT carmengarciaruiz mitochondrialgshreplenishmentasapotentialtherapeuticapproachforniemannpicktypecdisease AT josecfernandezcheca mitochondrialgshreplenishmentasapotentialtherapeuticapproachforniemannpicktypecdisease |